Abstract: Two-component pharmaceutical compositions for topical application to the human or animal body comprising two miscible liquid phases having different lipophilicities and a drug dissolved in at least one liquid phase, each phase comprising at least one topically acceptable non-aqueous and non-volatile solvent.

Abstract: Compositions for oral administration for the treatment of gastric disorders comprising histamine H.sub.2 -receptor antagonist and antacid, optionally buffered to promote local absorption of the H.sub.2 -receptor antagonist, wherein the quantity of H.sub.2 -receptor antagonist per unit dosage form is less than 25 mg.

Abstract: A topical composition containing a dissolved drug or the like (e.g. hydrocortisone acetate) preferably in saturated solution, and a solubilizer (e.g. propylene glycol), and preferably water and an antinucleant, is applied to a water-wetted area of the body, such as the hair or scalp, such that, on mixing with the body water, the resultant drug concentration exceeds the saturated drug solubility in the initially formed resultant mixture, thus giving a supersaturated drug composition.

Abstract: A pharmaceutical composition for topical administration consisting of two liquid phases designed to be admixed in situ or prior to use. The first phase contains a dissolved drug, and is preferably saturated in the drug, while the second phase is a chemically or physically different liquid from that in the first phase and contains no drug, but is miscible with the first phase. The two liquids are selected so that, on admixture of suitable volumes of the phases, the resultant drug concentration exceeds the saturated drug solubility in the resultant mixture. This produces a liquid mixture supersaturated in drug, which has been found to increase the rate of drug penetration into the skin. The two liquid phases may be gels, and the drug may be hydrocortisone.At least one phase contains an antinucleant to improve stability of the resulting supersaturated solution.

Abstract: A nozzle insert for a nozzle of a striped paste dispenser has a hollow cylindrical body through which a first pasty material may be dispensed, the external surface of the hollow body having circumferentially spaced apart plateaus separated by grooves through which a second pasty material may be dispensed, the body preventing contact between the two pasty materials downstream of the discharge end of the insert.

Abstract: A pharmaceutical composition for topical administration consisting of two liquid phases designed to be admixed in situ or prior to use. The first phase contains a dissolved drug, and is preferably saturated in the drug, while the second phase is a chemically or physically different liquid from that in the first phase and contains no drug, but is miscible with the first phase. The two liquids are selected so that, on admixture of suitable volumes of the phases, the resultant drug concentration exceeds the saturated drug solubility in the resultant mixture. This produces a liquid mixture supersaturated in drug, which has been found to increase the rate of drug penetration into the skin. The two liquid phases may be gels, and the drug may be hydrocortisone.

Abstract: The acute liver toxicity effects of paracetamol are reduced by co-formulating with ascorbic acid derivatives (ascorbate anion bioprecursors) which produce high liver concentrations of ascorbate anion after oral administration of the co-formulation. A suitable ascorbate anion bioprecursor is ascorbyl 6-palmitate.

Abstract: The acute liver toxicity effects of paracetamol are reduced by co-formulating with sustained release ascorbic acid which produces high liver concentrations of ascorbate anion after oral administration of the co-formulation. A suitable form of sustained release ascorbic acid is prepared by microencapsulation of particles of ascorbic acid in membranes which act as microdialysis cells.

Abstract: A pharmaceutical composition having analgesic, anti-pyretic and anti-inflammatory activity and administration thereof in oral dosage form, comprising 2-(carbamoyl)phenyl-2-acetoxybenzoate as active ingredient and procedure for preparing such active ingredient. One or more pharmaceutically acceptable oral carriers are mixed with the active ingredient for oral administration in various dosage forms. The disadvantages of acetyl salicyclic acid and salicylamide are avoided.